Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (KBLB) completed its Atlas Gene Library by integrating every planned Project Atlas transgene into living commercial silkworm hosts.
The library enables more than 200 potential genetic configurations, which remain designs to investigate rather than tested fibers. Kraig aims to combine the full Atlas suite in one production strain and pursue greater strength, toughness and flexibility than its current spider silk production line. Testing will determine the properties of Atlas-derived fibers; the targeted performance has not yet been demonstrated.
Kraig Biocraft Laboratories (KBLB) completed its Project Atlas Gene Library by integrating every planned transgene into living commercial silkworm hosts. The company has entered the next phase of developing stable homozygous breeding lines for each transgene.
Those lines are intended to support the creation and evaluation of more than 200 potential genetic pairing configurations. Kraig plans to study how the technologies perform together and identify combinations for further development. Its ultimate objective is to combine the full suite of Atlas genes in a single production strain.
Kraig Biocraft Laboratories (KBLB) outlined its progress in scaling recombinant spider silk production as New York Fashion Week begins.
The company links growing fashion-industry interest in bio-based and innovative textiles to its spider silk fibers, produced by genetically engineered silkworms rather than fermentation and post-processing. Kraig Labs reported producing approximately 3.2 metric tons of recombinant spider silk cocoons in a single production cycle earlier this year, described as a world record, and expects higher volumes. The production model is designed to use existing global silk infrastructure for potential luxury, performance apparel, protective and other advanced-material applications. Kraig Labs’ biomaterials work was also featured on the cover of the March 2026 issue of National Geographic.
Kraig Biocraft Laboratories (KBLB) highlighted a recent Tech Times feature that examines the scientific basis and commercialization path of its recombinant spider silk platform. The article explains how Kraig Labs uses genetically engineered Bombyx mori silkworms as biological production systems, leveraging their existing silk glands to spin spider silk proteins at scale. Kraig Labs recently reported a new production record on August 24, 2026, lifting output by more than 30% over its prior milestone, achieved during the technically challenging rainy season. The company positions this as evidence that its silkworm-based platform can move spider silk from science fiction toward commercial reality. Its work in scaling spider silk production was also featured on the cover of the March 2026 issue of National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) reported a new record for recombinant spider silk production, increasing output by more than 30% versus its prior record cycle. This growth was achieved during the rainy season, which the company describes as the most technically challenging period for sericulture due to environmental instability and mulberry handling issues.
Kraig Labs managed the cycle under a constraint of limited usable mulberry leaves and stated that rearing capacity could have supported even higher output with more feedstock. The company is securing additional land to expand in-house mulberry production, targeting new capacity within two to three months. Management also highlighted a shift from batch to continuous rolling production, aiming to support commercial-scale spider silk supply in all seasons.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that CEO and founder Kim Thompson authored a thought leadership editorial in Biocompare titled “Beyond Therapeutics: The Next Chapter of Synthetic Biology Is Manufacturing.” According to Kraig Biocraft Laboratories, the article introduces an “authored biology” framework, emphasizing enhancing proven natural systems, such as engineered silkworms, to produce recombinant spider silk at commercial scale.
The piece contrasts lab protein production with full-scale manufacturing and argues that synthetic biology’s next phase will be defined by consistent, economical, large-scale production. The company notes this perspective reflects its multi‑year effort to scale spider silk and supports its positioning in biology-enabled manufacturing and biomaterials, recently highlighted in a March 2026 National Geographic cover feature.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that its recombinant spider silk technology is the focus of a new Veritasium YouTube episode released around August 3, 2026. The segment takes viewers inside Kraig Labs’ labs and production facilities, showing how genetically engineered silkworms produce commercial spider silk fibers.
Veritasium hosts spent a full day with Kraig Labs’ scientists and engineers, then conducted a Spider-Man-inspired strength demonstration at a climbing gym, suspending people from Kraig’s spider silk. According to the company, this is among its broadest public introductions yet and complements earlier visibility, including a March 2026 National Geographic cover feature on its spider silk production work.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that CEO and founder Kim Thompson is featured in an in-depth interview in Just Style, a global apparel and textile trade publication. The article highlights Kraig Labs’ commercial-scale ramp-up in recombinant spider silk, tracing output from grams to kilograms, then hundreds of kilograms, and most recently to 2.5 metric tons of cocoon produced early this summer.
Thompson outlined a target of 10 metric tonnes of recombinant spider silk cocoon per month in 2026, potentially within 60 days, and emphasized the plug-and-play nature of the company’s transgenic silkworms within existing silk infrastructure, which already produces over 150,000 metric tons annually. The piece also presents recombinant spider silk as a premium, rare material suited to high fashion and situates Kraig Labs’ biology-enabled production model within a broader shift toward farm-grown, lab-designed textiles, alongside recent visibility such as a March 2026 National Geographic cover feature.
Summary not available.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a featured Pulse 2.0 interview with CEO Kim Thompson covering recombinant spider silk technology, commercial-scale production and long-term strategy.
Thompson describes leveraging existing global silk infrastructure, advances in genetically engineered silkworms, expansion in Southeast Asia, and target monthly metric-ton-level production for apparel, luxury fashion, technical and defense textiles.